X hits on this document

157 views

0 shares

0 downloads

0 comments

40 / 61

Outcomes of a Prospective Trial  of Intravenous Milrinone For Exacerbations of Congestive Heart Failure OPTIME-CHF     JAMA 2002

Not indicated in routine use with standard medica therapy.

Conclusions

No difference in primary end point between Milrinone and placebo.

Higher instance of atrial arrhythmia and hypotension with Milrinone.

Milrinone is associated a 30% increase in mortality

Outcomes

Repeat hospitalization for cardiovascular causes within 60 days of discharge.

Primary Endpoints

Broad Population with systolic dysfunction

Without low output syndrome

949 patients

Enrolled

Randomized, Control, Double Blinded

Milrinone versus Placebo

Design

Document info
Document views157
Page views157
Page last viewedFri Dec 09 15:34:31 UTC 2016
Pages61
Paragraphs503
Words1542

Comments